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Abstract
Toll-like receptors (TLRs) play pivotal roles in the innate immune system and control inflammatory responses and adaptive
immunity. We previously evaluated associations between TLR7 and TLR8 gene SNPs and susceptibility to hepatitis C virus
(HCV) infection. Our results suggested that TLR7IVS2-151G and TLR8-129G alleles were present at higher frequency in males
of an HCV-infected group as compared to a control group (24.1% vs. 14.4%, p=0.028; 17.6% vs. 6.8%, p=0.004,
respectively). Based upon their recognition of single stranded viral RNA, this suggested that TLR7 and TLR8 played a
significant role in anti-HCV immune responses. Here, we studied the functional effects of these polymorphisms by analyzing
the mRNA expressions of TLR7 and TLR8 and cytokine production induced ex vivo by TLR7- and TLR8-specific agonists using
whole blood of subjects with different genotypes. The percentage of CD14+ cells from those with an AG haplotype that
expressed TLR7 and TLR8 was significantly lower, but higher in intensity compared to cells from those with GG and AC
haplotypes. Cells from those with an AG haplotype produced more IFN-a and less amounts of pro-inflammatory cytokines
upon stimulation. This suggests that variations in TLR7 and TLR8 genes might impair immune responses during HCV
infection.
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Introduction
Toll-like receptors (TLRs) are important pathogen recognition
receptors (PRRs) at the interface between a host and the
environment and are key molecules for both innate and adaptive
immunity [1]. TLR7 and TLR8, which share a high degree of
structural similarity, are located in the membranes of the
endosomal compartment and recognize viral single-stranded
RNA (ssRNA) [2,3,4]. TLR genetic variants and downstream
signalling molecules can influence the ability of affected individuals
to respond adequately to TLR ligands, which can result in their
altered susceptibility to or the course of infectious disease [5,6,7].
The number of reported genotypic profiles of TLRs is rapidly
expanding. However, the number of identified functional TLR
polymorphisms remains limited, and parts of some studies have
divergent results regarding the significance of polymorphisms and
even have contradictory observations [8].
We previously identified a single nucleotide polymorphism
(SNP) at IVS2-151 of TLR7 and a SNP resulting in a Met/Val
change at a start codon TLR8 associated (G/C) SNP at position
2129 in the TLR8 promoter region [9]. The polymorphism, TLR7
IVS2-151 G.A, changes the 2151 nucleotide of the second
intervening sequence (IVS-2 position 2151) from G to A and it’s
function is still unclear. In our Chinese population, TLR7 allele
frequencies were A at 77%, and G at 22%, and TLR8 allele
frequencies were C at 16%, and G at 83%. However, to date there
have been few studies on the functional effects of TLR7 and TLR8
gene polymorphisms.
Hepatitis C virus (HCV), a single-stranded RNA virus, infects
more than 170 million of the world’s population [10]. The
clinical outcome of HCV infection is highly variable, and genetic
factors involving innate immunity are likely to affect disease
susceptibility and disease progression after infection. A key aspect
of the antiviral innate immune response is the synthesis and
secretion of type I interferons (IFN), such as IFN-a and IFN-b
[11]. Based on their recognition of single stranded viral RNA,
TLR7 and TLR8, both of which genes are located on the X
chromosome [12], have been suggested to play important roles in
antiviral immune responses induced by IFN and inflammatory
cytokines.
Recent reports have indicated that robust TLR7 and TLR8
agonists decrease the amounts of HCV RNA in HCV-infected
patients [13,14]. The specific aims of this study were to evaluate
possible associations between the susceptibility to HCV infection
and TLR7 and TLR8 polymorphisms and to compare the
expressions and functions of TLR7 and TLR8 variants.
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Allele and haplotype frequencies in chronic hepatitis C
patients
The genotypes involving TLR7 and TLR8 SNPs of 264 patients
with chronic HCV infection and 243 control subjects were
analyzed. The distributions of the allele and haplotype frequencies
for the TLR7 IVS2-151 G.A (rs179009) and TLR8 -129G.C
(rs3764879) polymorphisms are summarized in Table 1. The
frequency of TLR7 IVS2-151G was significantly higher in male
chronic HCV infection patients than control subjects (24.1%
versus 14.4%; p=0.028), with an odds ratios (OR) of 1.89 (95%
CI=1.06 to 3.33). TLR8 -129C also had a significantly higher
frequency in male chronic HCV infection patients than controls
(17.6% versus 6.8%; p=0.004); OR=2.91 (95% CI=1.38 to
6.13). However, no associations were found between chronic HCV
infection and TLR7 and TLR8 polymorphisms among females
(Table 1). Due to X skewing might affect the interpretation of data
in female, we disregard TLR7 SNP heterozygous females from
analysis [15] and got a significant difference in homozygous TLR7
IVS2-151genotypes among controls and hepatitis C female
patients (p=0.021; OR=8.55,95% CI=0.99 to 73.4).
Based on haplotype analysis for homo- and hemizygous
subjects, the frequency of wild TLR7 IVS2-151A/TLR8 -129G
(AG) was significantly lower in chronic HCV infection patients
than control subjects (65.3% versus 83.2%; p,0.001). Moreover,
the haplotypes TLR7 IVS2-151A/TLR8 -129C (AC) and TLR7
IVS2-151G/TLR8 -129G (GG) increased the risk for chronic HCV
infection compared to wild type TLR7 IVS2-151A/TLR8 -129G
(AG), with OR=2.67 (95% CI=1.36 to 5.22; p=0.003) and
OR=2.49 (95% CI=1.43 to 4.34; p=0.001), respectively
(Table 2). Taken together, those with mutant variants of TLR7
and TLR8 had higher susceptibility to chronic HCV infection than
those with wild type alleles.
TLR7 and TLR8 expression studies
Figure 1 shows the results of quantitative determinations for
TLR7 and TLR8 mRNA expressions in healthy male volunteers
with different TLR7 and TLR8 haplotypes. Individuals with the
TLR7 IVS2-151A/TLR8 -129C (AC) haplotype had higher TLR7
and TLR8 mRNA expressions. TLR8 mRNA expression for those
with the AC wild type was significantly higher than for those with
the AG and GG haplotypes (p=0.008; 0.001; respectively).
Figure 2 shows the results of FASC analysis for the intracellular
TLR7 and TLR8 protein expressions in monocytes from 37
healthy male subjects with different TLR7 and TLR8 genotypes:
AG haplotype, N=17; GG haplotype, N=9; AC haplotype,
N=11. Those with the AG haplotype had a significantly lower
percentage of CD14+ cells that expressed TLR7 (61.765.4%)
compared to those with the GG haplotype (68.066.9%; p=0.089)
and the AC haplotype (68.068.3%; p=0.066; Figure 2A). Also,
the percentage of CD14+ cells from subjects with the AG
haplotype that expressed TLR8 (61.564.9%) was significantly
lower compared to cells from those with the GG haplotype
(68.367.1%; p=0.060) and the AC haplotype (68.168.3%;
p=0.048; Figure 2C). In contrast, the mean fluorescence
intensities of TLR7 and TLR8 expressions were significantly
higher in cells from subjects with the AG haplotype compared to
cells from those with the GG and AC haplotypes (Figure 2B &
2D).
Ex vivo stimulation assays
To examine whether the TLR7 and TLR8 SNPs affected
cytokine induction, we stimulated whole blood samples from
healthy donors using TLR7 and TLR8 specific agonists. Whole
blood was obtained from healthy male volunteers with
different haplotypes and exposed ex vivo to a TLR7-specific
agonist (3M-001) or a TLR8-specific agonist (3M-002) for
12 hours, after which the supernatants collected for cytokines
assays. In response to 3M-001, whole blood from those with
the wild type (AG) haplotype had higher IFN-a production as
compared to the GG and AC haplotypes (p=0.003 and 0.004,
respectively; Figure 3A). However, lower IL-1ß production
from those with AG haplotyp compared to the GG haplotype
Table 1. Genotype frequencies of TLR7 and TLR8
polymorphisms for HCV chronic infection and control groups.
HCV Control p OR
N=264 N=243 (95%CI)
TLR7 IVS2-151 (rs179009)
Male N=187 N=146
A 142 (75.9)
a 125 (85.6) 0.028* 1.89 (1.06–3.33)
G 45 (24.1) 21 (14.4)
Female N=77 N=97
AA 47 (61.0) 67 (69.1) 0.070
AG 24 (31.2) 29 (29.9) 0.021
# 8.55 (0.99–73.4)
GG 6 (7.8) 1 (1.0)
A allele 118 (76.6) 163 (84.0) 0.149 1.45 (0.87–2.40)
G allele 36 (23.4) 31 (16.0)
TLR8 -129 (rs3764879)
Male N=187 N=146
C 33 (17.6) 10 (6.8) 0.004** 2.91 (1.38–6.13)
G 154 (82.4) 136 (93.2)
Female N=77 N=97
CC 2 (2.6) 1 (1.0) 0.554
CG 21 (27.3) 24 (24.7) 0.411
#
GG 54 (70.1) 72 (74.2)
C allele 25 (16.2) 26 (15.5) 0.788 1.08 (0.61–1.88)
G allele 129 (83.8) 168 (84.5)
aNo (%) of subjects.
*P,0.05;
**P,0.001; compared with control group.
#Comparison of female subjects with homozygotes.
doi:10.1371/journal.pone.0026235.t001
Table 2. Haplotype frequencies of TLR7 and TLR8 genes for
HCV chronic infection and control groups.
Haplotype HCV Control
N=225
# N=220
#
TLR7 IVS2-151A/TLR8 -129G (AG) 147 (65.3)* 183 (83.2)
a
TLR7 IVS2-151A/TLR8 -129C (AC) 30 (13.3)* 14 (6.4)
TLR7 IVS2-151G/TLR8 -129G (GG) 44 (19.6)* 22 (10.0)
TLR7 IVS2-151G/TLR8 -129C (GC) 4 (1.8)* 1 (0.5)
#Heterozygous female individuals are excluded.
aNo (%) of subjects.
*P,0.05; HCV group was compared with control group.
doi:10.1371/journal.pone.0026235.t002
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decreased pro-inflammatory responses compared to the other
haplotypes, as significant differences were observed for IL-6
and TNF-a after 3M-002 stimulation (p=0.050 and 0.037,
respectively; Figure 3G and 3I).
Discussion
Although an antiviral immune response is staged in almost all
patients infected with HCV, only some of these patients achieve a
spontaneous resolution and the factors that determine the quality
Figure 1. Quantitative TLR7 and TLR8 mRNA expression of individuals with different genotype by RT-PCR. The total RNA was extracted
from buffy coat of male volunteers. The relative expression of TLR7 (A) and TLR8 (B) mRNA was reverse transcribed and obtained by using the
2
(2DDCT) method which was normalized with an endogenous control, glyceraldehydes-3 phosphate dehydrogenase (GAPDH). Each dot represents an
individual, (N) represent individuals with TLR7 IVS2-151A/TLR8 -129G genotype, (&) represent individuals with TLR7 IVS2-151G/TLR8 -129G genotype
and (m) represent those with TLR7 IVS2-151A/TLR8 -129C genotype. The horizontal bars represent mean value. *: p-value,0.05. **: p-value,0.001.
doi:10.1371/journal.pone.0026235.g001
Figure 2. Intracellular TLR7 and TLR8 protein expression in monocytes of health male subjects with different genotypes of TLR7
and TLR8. The TLR7 and TLR8 protein expressions in monocytes of different genotypes from health male subjects were assessed by FACS. By double
staining strategy with anit-CD14-PE conjugated antibody and monoclonal FITC conjugated TLR7 or TLR8 antibodies. (A) TLR7 expression represented
as percentage of CD14-positive cells; (B) TLR7 expression represented as MFI; (C) TLR8 expression represented as percentage of CD14-positive cells;
(D) TLR8 expression represented as MFI. Each dot represents an individual, (N) represent individuals with TLR7 IVS2-151A/TLR8 -129G genotype, (&)
represent individuals with TLR7 IVS2-151G/TLR8 -129G genotype and (m) represent those with TLR7 IVS2-151A/TLR8 -129C genotype. The horizontal
bars represent mean value. *: p-value,0.05. **: p-value,0.001.
doi:10.1371/journal.pone.0026235.g002
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addition to viral factors, host factors, including age, gender and
genetic factors, influence the spontaneous outcome after HCV-
infection, the progression to chronic disease and the response to
therapy [17]. Thus, a role for TLR7 and TLR8 in the immune
response against HCV, a single-stranded RNA virus, is conceiv-
able, as an antiviral effect of TLR7 stimulation has been
demonstrated in early clinical studies [13].
Our results showed that the TLR7IVS2-151G and TLR8-129G
polymorphisms were statistically significantly more frequent in
male subjects with chronic HCV infection as compared to
controls. In addition, our results suggest that the TLR7 (IVS2-
151A.G) and TLR8 (-129G.C) polymorphisms also altered these
gene expressions when quantified by mRNA. However, ex vivo
stimulation assays demonstrated that these TLR7 and TLR8
polymorphisms resulted in significantly different production of
IFN-a, IL-1ß and IL-6 after stimulation with a TLR7 agonist,
whereas only IL-1ß and TNF-a production were altered after
stimulation with a TLR8 agonist (Figure 3). Taken together, the
immune cells from those with the wild type AG haplotype
produced more IFN-a and less amounts of pro-inflammatory
cytokines upon stimulation. We propose the variations in the
TLR7 and TLR8 genes may impair the immune responses to HCV
due to less IFN-a production during stimulation.
The distributions of TLR7 IVS2-151G.A (rs179009) and TLR8-
129G.C (rs3764879) allelic frequencies in other populations are
shown in Table 3. In our Taiwanese study population, the
genotype distributions for the TLR7 IVS2-151G.A and TLR8-
129G.C polymorphisms were: 413 had the A allele (15.0%), 73
had the G allele (85.0%), and 46 had the C allele (9.5%), and 440
had the G allele (90.5%), respectively. Compared with other ethnic
populations from the website of the international HapMap project,
statistical analysis did not reveal a difference in allele frequencies
for the TLR7 IVS2-151G.A polymorphism when comparing our
population with Caucasians and Japanese, but there was a
significant difference between our results and those from a
Nigerian population (p=0.009).
In our previous study, SNPs resulting in a Met/Val change at
the start codon for TLR8 and a (G/C) SNP at position 2129 in the
TLR8 promoter region were shown to be in linkage [9]. As
compared to other ethnic populations, Taiwanese exhibited an
allele frequency for TLR8 Met1Val and TLR8 -129 G/C opposite
to those of Caucasians and Nigerians (Table 3). The TLR8 -129
G/C linkage with the TLR8 A1G polymorphism alters the start
ATG of TLR8 into a GTG triplet. A methionine located at
position 4 could be used as an alternate start codon, resulting in a
truncated TLR8 (1038 aa vs. 1041 aa) with a shorter signal
peptide. The functional effect of this mutation may result in a
more rapid decay of TLR8 mRNA or may affect protein function
[18].
In overexpression assays, it has been demonstrated that a TLR8
A1G polymorphism resulted in impaired NF-kB activation in vitro.
The mutated receptor variant was associated with modulating the
cytokine secretion profiles and lipid mediator synthesis patterns in
monocytes and neutrophils [18]. The functional TLR8 variant
may have implications for assessing the risks for individual patients
infected with HIV and other RNA viruses [18]. In this study we
also demonstrated that those with the TLR8-129G associated
TLR8 variant had a higher susceptibility to HCV infection. This is
consistent with previous studies [19,20].
Undesired self-destructive immune responses result in a loss of a
robust immune response against HCV replication and perturba-
tions in virus eradication [21,22]. An increasing body of evidence
suggests a role for innate immunity in the control of HCV
infection, although the precise mechanisms have not been defined.
The potency of an innate immune response is genetically
predetermined and can result in HCV clearance [22]. TLR7
and TLR8 are PRRs of interest in the setting of HCV-infection as
they can bind ssRNAs and lead to the production of large amounts
of the antiviral cytokine interferon-a by dendritic cells [23].
Therefore, we hypothesized that genetic variants of TLR7 and
TLR8 might influence the immune response against HCV.
We selected TLR7- and TLR8-specific agonists for whole blood
ex vivo stimulation. Whole blood samples from subjects with the
wild type AG haplotype had higher IFN-a production as
compared to the GG and AC haplotypes upon stimulation with
5 mM of 3M-001, but there was no induction of IFN-a after
stimulation with the TLR8 agonist 3M-002 regardless of
haplotype. The reason may be that plasmacytoid dendritic cells
in peripheral blood, which express TLR7 but not TLR8, are the
primary producers of IFN-a [23].
In contrast, upon stimulation with 5 mM of 3M-002, whole
blood samples from those with the AG haplotype exhibited
decreased pro-inflammatory responses reflected by IL-1b and
TNF-a induction. High levels of these cytokines have been shown
to be correlated with increased liver damage in HCV patients
[16,17,24,25]. Thus, male volunteers with the TLR7 IVS2-151A/
TLR8 -129G haplotype had higher induced interferon production
and lower amounts of inflammatory cytokines than those with the
GG and AC haplotypes after ex vivo whole blood stimulation with
TLR7 and TLR8 agonists.
The allele frequencies of both variations were gender-depen-
dent. Because the TLR7 and TLR8 genes are located on the X-
chromosome [4], gender-specific effects come as no surprise. The
Table 3. Allele frequencies of TLR7 and TLR8 polymorphisms
in different ethnic groups.
Gene SNP (dbSNP No)
Nigeria Caucasian Japanese Taiwanese
TLR7 (X allele) IVS2-151 G.A (rs179009)
A allele 0.750* 0.817 0.807 0.850
G allele 0.250 0.183 0.193 0.150
TLR8 (X allele) -129G.C (rs3764879)
C allele 0.725** 0.775** 0.273** 0.095
G allele 0.275 0 .225 0.727 0.905
Allele frequencies of these ethic groups were retrieved from web of
International HapMap project.
*P,0.05,
**P,0.001, comparing non-Taiwanese ethnic group with Taiwanese.
doi:10.1371/journal.pone.0026235.t003
Figure 3. Ex vivo cytokines production upon TLR7 or TLR8 agonist stimulation during whole blood culture. Fresh whole blood
specimens from male volunteers were stimulated with TLR7 agonist (3M-001) (A–E) or TLR8 agonist (3M-002) (F–J) for 12 hr. The concentrations of
IFN-a, IL-1b, IL-6, TNF-a, and MIP-1a concentrations in the supernatant were measured by high sensitive IFN-a ELISA and Luminex100 system. Each
dot represents an individual, (N) represent individuals with TLR7 IVS2-151A/TLR8 -129G genotype, (&) represent individuals with TLR7 IVS2-151G/TLR8
-129G genotype and (m) represent those with TLR7 IVS2-151A/TLR8 -129C genotype. The horizontal bars represent mean value.
doi:10.1371/journal.pone.0026235.g003
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tissue-dependent process that may affect the analysis of the effects
of X-chromosomal variations [15,26]. Therefore, associations
between chronic HCV chronic infection and TLR7 and TLR8
polymorphisms were not found among females in our study. Due
to the accumulating data on genetic polymorphisms in HCV-
infection [22,23,24], we suggest that patient’s sex needs to be taken
into account when future individual risk profiles for HCV infection
are generated.
Our results suggest that TLR7 and TLR8 variants have
functional relevance in the setting of HCV-infection by conferring
susceptibility to infection. The TLR7 and TLR8 variants result in
reduced IFN-a release. Accordingly, this could be responsible for a
lower level of immune activation and explain the higher
susceptibility to chronic HCV chronic infection among males
with these mutations. Thus, our results support the concept that
HCV infection depends on TLR7/8-mediated immune activation.
It will be of interest to observe the results from further trials on the
use of TLR agonists, such as isatoribine or CpG-DNA [13,27], for
the treatment of chronic HCV infection and how these are
correlated with the genetic markers of the associated genes.
A different approach for investigating the roles of TLR7 and
TLR8 SNPs in the resolution of HCV-infection would require a
comparison of patients who are chronically infected with HCV
with individuals that have spontaneously cleared infections.
Unfortunately, patients with proven spontaneous recovery from
HCV-infection were not included in this study. Therefore, we
investigated the effects of these mutations in healthy volunteers. In
humans, TLR7 is expressed by plasmacytoid DCs and B cells
[28,29], whereas TLR8 is abundant on monocytes and monocyte-
derived DCs [30,31]. Our results showed that subjects with the
TLR7 IVS2-151A/TLR8 -129G haplotype had a lower percentage
of monocytes that expressed TLR7 or TLR8, but these cells had
higher intensity expressions compared to cells from those with
other genotypes.
In conclusion, the results presented here demonstrate a
protective effect of the TLR7 IVS2-151A/TLR8 -129G haplotype
against HCV chronic infection. We showed that the presence of
this mutation leads to lower IFN-a and higher pro-inflammatory
cytokine production. The modulation of immune responses is not
only compatible with the restriction of HCV infection, but leads us
to propose that future studies should address the relevance of these
polymorphisms during the clinical course of HCV infection. The
results of this study may have implications for assessing individual
patient’s risk profiles, as well as for the use of TLR agonists in the
prevention of or in therapy for HCV infection.
Materials and Methods
Study participants
We recruited a population of 264 chronic hepatitis C patients
(including 187 men and 77 female adults) according to suggestions
by Lu et al [32] ( mean age 52.9615.7 years) and 243 control
subjects (including 146 men and 97 female adults) who were anti-
HCV negative ( mean age 48.3619.8 years) for determinations of
TLR7 and TLR8 gene variations. Patients with HBV or HIV
infection were excluded. Chronic HCV infection was proven by
detection of anti-HCV or HCV RNA in the patient’s sera over a
period of at least 6 months. Serum activity of aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) were
recorded. The detail demographic characteristics of study subjects
are summarized in Table S1. Informed consent was obtained from
all individuals. This study was approved by the E-DA Hospital
ethics committee.
Genotyping of TLR7 and TLR8 variants
Genomic DNA was extracted from EDTA blood using spin
columns with a QIAampH Blood Mini Kit (Qiagen, Hilden,
Germany). Genotyping for the TLR7 (IVS2-151A.G) and TLR8
(-129 G.C) polymorphisms were analyzed by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP)
as previously described [9].
Determinations of TLR7 and TLR8 mRNA expressions by
quantitative reverse transcription polymerase chain
reaction (RT-PCR)
Healthy male volunteers (laboratory staff members and college
students) were randomly selected from among healthy male
subjects after TLR7 IVS2-151 and TLR8-129 genotyping. Total
RNA was extracted from peripheral blood samples using a Qiagen
RNA Blood isolation kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. Complementary DNA (cDNA)
was synthesized by reverse transcription with oligo-dT primers.
The mRNA expressions of TLR7 and TLR8 were analyzed by
quantitative RT-PCR. Fluorescence real-time PCR analysis used
an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems, Warrington, WA). The PCR amplification reaction
used the conditions: 50uC for 2 min, 95uC for 15 min, and 40
cycles at 95uC for 15 sec followed by 58uC for 1 min. We used the
comparative CT (DDCT) method, in which CT is the threshold
cycle number that is the minimum required for sample detection.
The arithmetic formula for the DCT method is the difference in
CT for the TLR7 or TLR8 gene and a housekeeping gene, GAPDH
(DCT=CT
TLR7 or CT
TLR8-CT
GADPH). Then, the relative
amounts of mRNA were normalized to the lowest TLR7 or
TLR8 mRNA level given by 2
2DDCT and given as the logarithm of
2
2DDCT.
Intracellular TLR7 and TLR8 protein expression assay
The intracellular protein expressions of TLR7 and TLR8 in
monocytes from healthy male volunteers with different haplotypes
were analyzed by flow cytometric analysis. First, 250 mL of freshly
collected EDTA-whole blood was stained with 5 mL of PE-
conjugated anti-CD14 antibody (BD Biosciences, San Jose, CA)
for 30 min at room temperature. Red blood cells were lysed by
adding 2 mL of working 16 BD FACSTM Lysing Solution into
each reaction tube for 10 min at room temperature, and then
excess unbound antibody was washed away with phosphate
buffered saline (PBS). For intracellular staining, the remaining
leukocytes were fixed and permeabilised by adding 250 mLo f
Fixation and Permeabilization Solution (BD Biosciences, San Jose,
CA) for 20 min at 4uC, after which cells were incubated with 2 mL
of FITC-conjugated anti-TLR7 (IMGENEX, San Diego, CA) or
anti-TLR8 (IMGENEX, San Diego, CA) diluted with 18 mLo f
10% foetal bovine serum in PBS containing 0.2% saponin for 1 hr
at 4uC. Cells were finally resuspended in PBS and analyzed on a
FACSCalibur flow cytometer with WinMDI98 software (BD
Biosciences, San Jose, CA).
Cytokines released after ex vivo whole blood stimulation
Incubation of human whole blood in the presence of different
stimuli was as described previously [33]. Briefly, fresh heparinised
blood from healthy volunteers was diluted 2-fold with Hank’s
balanced salt solution (HBSS). The blood was incubated with
synthetic specific agonists prepared by 3M Pharmaceuticals
(St. Paul, MN) for TLR7 [34] (5 mM 3M-001, N-[4-(4-
amino-2-ethyl-1H -imidazo[4,5-c]quinolin-1-yl)butyl]methanesul-
fonamide; formula, C17H23N5O2S; m.w., 361) and TLR8 [34]
TLR7 and TLR8 Gene Variations and HCV Infection
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C13H13N3S; m.w., 243) for 12 hours in the presence of 5% CO2
at 37uC. Then, the cells were pelleted by centrifugation (4006g for
2 min), and the cell-free supernatants were stored at 270uC prior
to cytokine determinations. All experiments and measurements
were carried out blindly with regard to the polymorphism status of
the donors.
Cytokine amounts were quantified using Luminex technology,
which utilizes microspheres as the solid support for conventional
sandwich immunoassay to simultaneously measure multiple
cytokines. The combinations of different types of beads allows
for the simultaneous measurements of IFN-a, IL-1b, IL-6, TNF-a,
and MIP-1a (Biosource International, Camarillo, CA). The
cytokine kit assay used the manufacturer’s protocol. Briefly, to
each designated pre-wetted well with a filter bottom in a 96-well
microplate format (Millipore, Billerica, MA), a bead suspension
was added, and the beads were washed and blocked for 10 min
with PBS/bovine serum albumin. To generate a standard curve,
appropriate standards were prepared in diluents. Standards and
samples (50 ml) were diluted 1:1 with assay diluents and pipetted
into duplicate wells. The plates were incubated for 1 h at room
temperature on a microtitre shaker. After washing with PBS, a
phycoerythrin (PE)-conjugated detection antibody cocktail was
added to each well and the plates were incubated for an additional
45 min in the dark. Wells were washed twice, an assay buffer was
added to each well, and samples were analyzed using the Luminex
system (Bio-Rad Laboratories, Hercules, CA). The experimental
data were analyzed using a five-parameter standard curve that was
fit to the results for the provided standards.
Statistical analysis
Genotype frequencies of TLR7 and TLR8 polymorphisms were
compared between chronic HCV-infected patients and control
subjects using chi-square tests. Quantitative results from three
groups are given as means 6 SD and assessed with nonparametric
Kruskal-Wallis test. A p-value,0.05 was considered statistically
significant. SPSS (version 14.01) was used for data management
and statistical analyses and Graph Pad Prism 5 software was used
to generate the figures.
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